Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DWP14012 + celecoxib
- Development stage
- Unknown
- Lead developer
- Daewoong Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**DWP14012 + celecoxib** is a combination investigational oral therapy comprising DWP14012 (also known as fexuprazan or abeprazan, a potassium-competitive acid blocker) and celecoxib (a selective cyclooxygenase-2 inhibitor). DWP14012 reversibly inhibits the gastric H+,K+-ATPase enzyme, resulting in acid suppression in the stomach, and is being developed as an alternative to proton pump inhibitors for acid-related disorders. Celecoxib acts as a COX-2-selective nonsteroidal anti-inflammatory drug (NSAID), used to reduce inflammation and pain. This combination would be expected to provide gastrointestinal protective effects (from DWP14012) along with anti-inflammatory and analgesic action (from celecoxib), which may be useful especially when using NSAIDs in patients at risk for gastric mucosal injury[1][4].
- Other names
- fexuprazan + celecoxib
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on DWP14012 + celecoxib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DWP14012 + celecoxib.